Zobrazeno 1 - 10
of 631
pro vyhledávání: '"S. Badve"'
Autor:
C.B Koppiker, D.A Kelkar, M. Kulkarni, M. Pai, U. Dhar, C. Deshmukh, B. Varghese, N. Jumle, V. Zamre, S. Kadu, A. Joshi, R. Unde, R. Banale, N. Namewar, P. Vaid, G. Thomas, S. Nare, J. Pereira, S. Badve
Publikováno v:
Breast, Vol 68, Iss , Pp S105- (2023)
Externí odkaz:
https://doaj.org/article/cfe37743d6f2490492b8d418bf0afb9d
Publikováno v:
Breast, Vol 68, Iss , Pp S111- (2023)
Externí odkaz:
https://doaj.org/article/a82c785bdfc344febffa6e32d5f12928
Publikováno v:
Kidney International Reports, Vol 6, Iss 4, Pp S134- (2021)
Externí odkaz:
https://doaj.org/article/1f7a5ad9e49f42018e98fef291b4f7fe
Autor:
Mayar Allam, Thomas Hu, Jeongjin Lee, Jeffrey Aldrich, Sunil S. Badve, Yesim Gökmen-Polar, Manali Bhave, Suresh S. Ramalingam, Frank Schneider, Ahmet F. Coskun
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-21 (2022)
Abstract The Immunoscore is a method to quantify the immune cell infiltration within cancers to predict the disease prognosis. Previous immune profiling approaches relied on limited immune markers to establish patients’ tumor immunity. However, imm
Externí odkaz:
https://doaj.org/article/9e5070068683451ebbd1a83b5eb66b7b
Autor:
Sunil S. Badve, Sanghee Cho, Xiaoyu Lu, Sha Cao, Soumya Ghose, Aye Aye Thike, Puay Hoon Tan, Idris Tolgay Ocal, Daniele Generali, Fabrizio Zanconati, Adrian L. Harris, Fiona Ginty, Yesim Gökmen-Polar
Publikováno v:
Cancers, Vol 14, Iss 16, p 3916 (2022)
Tumor-infiltrating lymphocytes (TILs) are prognostic in invasive breast cancer. However, their prognostic significance in ductal carcinoma in situ (DCIS) has been controversial. To investigate the prognostic role of TILs in DCIS outcome, we used diff
Externí odkaz:
https://doaj.org/article/8a657860535842f4bad7ebfbd7a7ff3a
Autor:
Sunil S, Badve, Yesim, Gökmen-Polar
Publikováno v:
American Society of Clinical Oncology Educational Book. :73-81
The increasing use of neoadjuvant therapy has resulted in therapeutic decisions being made on the basis of diagnostic needle core biopsy. For many patients, this method might yield the only fragment of tumor available for biomarker analysis, necessit
Autor:
Allison W. Kurian, George W. Sledge, James M. Ford, Scarlett L. Gomez, Kathleen Horst, Robert B. West, Christina N. Curtis, Sunil S. Badve, Melinda L. Telli, Joseph Rigdon, Caroline A. Thompson, Tina Seto, Maya B. Mathur, Emma Pierson, Manisha Desai, Summer S. Han, Natasha Purington, Anosheh Afghahi
Supplemental Figure 1. Patient inclusion and exclusion criteria. TNBC: triple negative breast cancer; ALC: absolute lymphocyte count; nSES: neighborhood socioeconomic status. Supplemental Figure 2a and 2b. Association between minimum lymphocyte count
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21e229c6b31b22fe96461112c719ca50
https://doi.org/10.1158/1078-0432.22464414
https://doi.org/10.1158/1078-0432.22464414
Autor:
Allison W. Kurian, George W. Sledge, James M. Ford, Scarlett L. Gomez, Kathleen Horst, Robert B. West, Christina N. Curtis, Sunil S. Badve, Melinda L. Telli, Joseph Rigdon, Caroline A. Thompson, Tina Seto, Maya B. Mathur, Emma Pierson, Manisha Desai, Summer S. Han, Natasha Purington, Anosheh Afghahi
Purpose: Tumor-infiltrating lymphocytes (TIL) in pretreatment biopsies are associated with improved survival in triple-negative breast cancer (TNBC). We investigated whether higher peripheral lymphocyte counts are associated with lower breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08468c8f61ba3b2598416fd5b077d5cb
https://doi.org/10.1158/1078-0432.c.6525711.v1
https://doi.org/10.1158/1078-0432.c.6525711.v1
Autor:
Sunil S. Badve, Nancy E. Davidson, Joseph A. Sparano, George W. Sledge, Ann Thor, Sven Müller, Kirsten Vang Nielsen, Tamara N. Shenkier, Edith A. Perez, Melody A. Cobleigh, Maura N. Dickler, Julie R. Gralow, Kathy D. Miller, Guanglong Jiang, Lang Li, Gail Vance, Fei Shen, Milan Radovich, Robert J. Gray, Bryan P. Schneider
PDF file - 121K, Table 1. Supplemental Table 1. Comparison of the Patients Analyzable for VEGFA Amplification to All Patients Enrolled on E2100 Table 2. Estimated Progression Free Survival treatment hazard ratios (arm A vs. arm B) and 95% confidence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c84628500a797ceea4c46f6f1b711b2
https://doi.org/10.1158/1078-0432.22449660.v1
https://doi.org/10.1158/1078-0432.22449660.v1
Autor:
Sunil S. Badve, Nancy E. Davidson, Joseph A. Sparano, George W. Sledge, Ann Thor, Sven Müller, Kirsten Vang Nielsen, Tamara N. Shenkier, Edith A. Perez, Melody A. Cobleigh, Maura N. Dickler, Julie R. Gralow, Kathy D. Miller, Guanglong Jiang, Lang Li, Gail Vance, Fei Shen, Milan Radovich, Robert J. Gray, Bryan P. Schneider
Purpose: Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100. The associations betwe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45f822147b99a3f6e260a798dc86fa91
https://doi.org/10.1158/1078-0432.c.6521718
https://doi.org/10.1158/1078-0432.c.6521718